DCT

1:26-cv-00988

Eli Lilly Co v. Zydus Lifesciences Global FZE

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Eli Lilly & Company v. Zydus Lifesciences Global FZE, 1:26-cv-00988, D. Del., 08/06/2026
  • Venue Allegations: Venue is alleged based on Defendants' business operations and purposeful availment of the district, including regularly engaging in patent litigation in Delaware. For the foreign defendants, venue is also asserted under Federal Rule of Civil Procedure 4(k)(2).
  • Core Dispute: Plaintiff alleges that Defendants' submission of Abbreviated New Drug Applications (ANDAs) to market generic versions of the diabetes and weight-loss drugs Mounjaro® and Zepbound® constitutes an act of infringement of nine U.S. patents covering the drug's active ingredient, tirzepatide, its formulations, and methods of use.
  • Technical Context: The technology involves tirzepatide, a dual-agonist peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, a class of drugs with significant market application for treating type 2 diabetes and obesity.
  • Key Procedural History: This is a Hatch-Waxman action initiated after Plaintiff received "Notice Letters" dated July 13, 2026, informing it of Defendants' ANDA filings containing Paragraph IV certifications. These certifications assert that the patents-in-suit are invalid, unenforceable, or will not be infringed by the proposed generic products. The complaint was filed within the 45-day statutory window, triggering a 30-month stay of FDA approval for the ANDAs. All asserted patents are listed in the FDA's "Orange Book" for Mounjaro® and/or Zepbound®.

Case Timeline

Date Event
2018-06-22 Priority Date for '820, '623, '755, '756, '404 Patents
2018-07-23 Priority Date for '987, '382, '758, '740 Patents
2022-05-13 FDA grants approval for Mounjaro® (tirzepatide)
2022-06-14 '820 Patent issues
2023-11-08 FDA grants approval for Zepbound® (tirzepatide)
2024-03-05 '623 Patent issues
2025-05-13 '987 Patent issues
2025-07-01 '382 Patent issues
2025-10-28 '755 Patent issues
2025-10-28 '756 Patent issues
2025-10-28 '758 Patent issues
2026-05-05 '740 Patent issues
2026-05-19 '404 Patent issues
2026-07-13 Date of Defendants' Notice Letters
2026-07-14 Plaintiff receives Defendants' Notice Letters
2026-08-06 Complaint filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,357,820 - "GIP/GLP1 Agonist Compositions"

  • Issued: June 14, 2022 (Compl. ¶25)

The Invention Explained

  • Problem Addressed: The patent describes a need for compositions of the GIP/GLP1 co-agonist peptide tirzepatide that have "acceptable stability and acceptable patient injection site experience" ('820 Patent, col. 2:22-25). Specifically, certain formulation components like citrate can cause painful stinging at the injection site ('820 Patent, col. 3:9-13).
  • The Patented Solution: The patent discloses a pharmaceutical composition that combines tirzepatide with specific concentrations of sodium chloride (NaCl) and dibasic sodium phosphate ('820 Patent, abstract; '820 Patent, col. 1:4-7). This formulation is designed to be approximately isotonic with body fluids to minimize injection site pain while also providing commercially acceptable shelf-life and in-use stability ('820 Patent, col. 3:20-28).
  • Technical Importance: Creating a stable, injectable formulation for a biologic drug that is well-tolerated by patients is critical for ensuring compliance with chronic therapy, which is particularly important for managing conditions like diabetes and obesity ('820 Patent, col. 2:11-14).

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 (Compl. ¶54).
  • Claim 1 requires:
    • A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;
    • NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; and
    • dibasic sodium phosphate.

U.S. Patent No. 11,918,623 - "GIP/GLP1 Agonist Compositions"

  • Issued: March 5, 2024 (Compl. ¶27)

The Invention Explained

  • Problem Addressed: The patent addresses the treatment of obesity, a chronic disorder for which effective and well-tolerated pharmaceutical options are needed ('623 Patent, col. 2:34-35). As with the '820 Patent, it also implicitly addresses the need for a stable and patient-acceptable formulation for administering the therapeutic peptide ('623 Patent, col. 2:38-41).
  • The Patented Solution: The patent claims a method of treating obesity by administering a specific formulation of tirzepatide. The claimed method involves administering a pharmaceutical composition with tirzepatide and other excipients (dibasic sodium phosphate, NaCl, and optionally phenol) within defined concentration ranges ('623 Patent, abstract; '623 Patent, claim 1).
  • Technical Importance: This patent provides method-of-use protection for a specific formulation of tirzepatide for treating obesity, extending patent coverage beyond the composition itself to its specific therapeutic application and securing its market position for that indication ('623 Patent, col. 3:6-9).

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 (Compl. ¶70).
  • Claim 1 requires:
    • A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof, wherein the composition comprises:
    • tirzepatide concentration from about 5 mg/mL to about 30 mg/mL;
    • dibasic sodium phosphate from about 0.67 to about 2.68 mg/mL;
    • NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and
    • optionally from about 3.0 mg/mL to about 7.0 mg/mL phenol.

U.S. Patent No. 12,295,987 - "Methods of Using a GIP/GLP1 Co-agonist for Diabetes"

  • Issued: May 13, 2025 (Compl. ¶29)
  • Technology Synopsis: The patent addresses the need for diabetes treatments that avoid the gastrointestinal side effects that have limited the effectiveness of prior GLP-1 agonists ('987 Patent, col. 1:53-62). The invention is a specific dose-titration method for a GIP:GLP-1 peptide, involving a four-step dose escalation (25%, 50%, 75%, and 100% of the final dose) to treat type 2 diabetes ('987 Patent, claim 1).
  • Asserted Claims: At least independent claim 1 is asserted (Compl. ¶88).
  • Accused Features: The proposed labeling for the generic Mounjaro® product is alleged to instruct and encourage the claimed dose escalation regimen for treating type 2 diabetes (Compl. ¶89).

U.S. Patent No. 12,343,382 - "Methods of Using a GIP/GLP1 Co-agonist for Therapy"

  • Issued: July 1, 2025 (Compl. ¶31)
  • Technology Synopsis: This patent discloses methods of using tirzepatide with specific dosing schedules. The invention covers a method of administering an "escalation dose" (e.g., 2.5 mg) followed by a "maintenance dose" (e.g., 5.0 mg), with each dose administered about once weekly for a minimum period, to treat type 2 diabetes or improve weight management ('382 Patent, claims 1, 11).
  • Asserted Claims: At least independent claims 1 and 11 are asserted (Compl. ¶¶107, 109).
  • Accused Features: The proposed labeling for the generic products is alleged to instruct the claimed escalation and maintenance dosing regimens for both treating type 2 diabetes and improving weight management (Compl. ¶¶108, 110).

U.S. Patent No. 12,453,755 - "GIP/GLP1 Agonist Compositions"

  • Issued: October 28, 2025 (Compl. ¶33)
  • Technology Synopsis: This patent is similar to the '623 Patent but claims a method of treating diabetes, rather than obesity. It covers a method of administering a pharmaceutical composition containing tirzepatide, dibasic sodium phosphate, NaCl, and optionally phenol within specific concentration ranges to a human in need of diabetes treatment ('755 Patent, claim 1).
  • Asserted Claims: At least independent claim 1 is asserted (Compl. ¶130).
  • Accused Features: The proposed labeling for the generic Mounjaro® product is alleged to instruct and encourage treating diabetes by administering the claimed formulation (Compl. ¶131).

U.S. Patent No. 12,453,756 - "GIP/GLP1 Agonist Compositions"

  • Issued: October 28, 2025 (Compl. ¶35)
  • Technology Synopsis: This patent claims a pharmaceutical composition of tirzepatide. The invention is a formulation comprising tirzepatide, a specific concentration range of NaCl, and having a specific pH range of about 6.5 to 7.5, which provides stability and patient tolerability ('756 Patent, claim 1).
  • Asserted Claims: At least independent claim 1 is asserted (Compl. ¶148).
  • Accused Features: The proposed generic products are alleged to be pharmaceutical compositions that meet the claim limitations regarding tirzepatide, NaCl concentration, and pH (Compl. ¶149).

U.S. Patent No. 12,453,758 - "Methods of Using a GIP/GLP1 Co-agonist for Diabetes"

  • Issued: October 28, 2025 (Compl. ¶37)
  • Technology Synopsis: This patent is similar to the '987 Patent but claims a method of improving weight management. It covers a specific four-step dose-titration regimen (25%, 50%, 75%, and 100% of the final dose) for a GIP:GLP-1 peptide with a particular potency ratio ('758 Patent, claim 1).
  • Asserted Claims: At least independent claim 1 is asserted (Compl. ¶165).
  • Accused Features: The proposed labeling for the generic Zepbound® product is alleged to instruct and encourage the claimed dose escalation regimen for improving weight management (Compl. ¶166).

U.S. Patent No. 12,616,740 - "Methods of Using a GIP/GLP1 Co-agonist for Therapy"

  • Issued: May 5, 2026 (Compl. ¶39)
  • Technology Synopsis: This patent claims a specific dose titration method for treating type 2 diabetes or obesity with tirzepatide. The method comprises a first 2.5 mg once-weekly dose for four weeks, followed by increasing the dose in 2.5 mg increments to a maintenance dose (5, 10, or 15 mg), with each increased dose administered for at least four weeks ('740 Patent, claims 1, 6).
  • Asserted Claims: At least independent claims 1 and 6 are asserted (Compl. ¶¶184, 186).
  • Accused Features: The proposed labeling for the generic products is alleged to instruct the claimed multi-step 2.5 mg incremental dosing regimen for treating type 2 diabetes and obesity (Compl. ¶¶185, 187).

U.S. Patent No. 12,629,404 - "GIP/GLP1 Agonist Compositions"

  • Issued: May 19, 2026 (Compl. ¶41)
  • Technology Synopsis: This patent is similar to the '756 Patent but with an additional limitation. It claims a pharmaceutical composition comprising tirzepatide, a specific concentration range of NaCl, and a specific pH range, wherein the composition is also "free of preservative" ('404 Patent, claim 1).
  • Asserted Claims: At least independent claim 1 is asserted (Compl. ¶207).
  • Accused Features: The proposed generic products are alleged to be pharmaceutical compositions that are free of preservative and meet the other claim limitations for tirzepatide, NaCl concentration, and pH (Compl. ¶208).

III. The Accused Instrumentality

  • Product Identification: The accused instrumentalities are Defendants' "Proposed ANDA Products" corresponding to Abbreviated New Drug Application (ANDA) Nos. 221364 and 221365 (Compl. ¶1). These are proposed generic versions of Lilly's Mounjaro® and Zepbound® (tirzepatide) autoinjectors in various strengths, including 2.5, 5, 7.5, 10, 12.5, and 15 mg/0.5 mL (Compl. ¶1).
  • Functionality and Market Context:
    • The active pharmaceutical ingredient in the Proposed ANDA Products is tirzepatide, a dual GIP/GLP-1 receptor agonist (Compl. ¶21; Compl. ¶48).
    • The products are described as sterile solutions for subcutaneous use, intended to be bioequivalent to Mounjaro® and Zepbound® (Compl. ¶22; Compl. ¶49).
    • The complaint alleges that upon FDA approval, these products will be marketed as direct competitors to Mounjaro® for improving glycemic control in patients with type 2 diabetes and to Zepbound® for chronic weight management (Compl. ¶1; Compl. ¶2). The complaint further alleges that the proposed product labels will instruct for their use in these indications (Compl. ¶50).

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

'820 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof; Defendants' Proposed ANDA Products are pharmaceutical compositions comprising tirzepatide, or a pharmaceutically acceptable salt thereof. ¶55 col. 3:20-22
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; The Proposed ANDA Products are alleged to comprise NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL. ¶55 col. 2:32-33
and dibasic sodium phosphate. The Proposed ANDA Products are alleged to comprise dibasic sodium phosphate or an equivalent thereof. ¶55 col. 2:41-42
  • Identified Points of Contention:
    • Scope Question: The complaint's allegation that the accused products contain "dibasic sodium phosphate or equivalent thereof" (Compl. ¶55) raises the question of whether Defendants' formulation contains the exact chemical claimed or a different phosphate buffer. If it is not the exact chemical, the infringement analysis will focus on whether the alternative constitutes an equivalent under the doctrine of equivalents.
    • Technical Question: A factual dispute may arise regarding the precise concentration of NaCl in the final manufactured product and whether it falls within the claimed range of 6.2 mg/mL to 9.5 mg/mL.

'623 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide... Defendants are seeking proposed labeling that allegedly "instructs and encourages treating obesity by administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide." ¶71 col. 3:6-9
wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL; The proposed labeling is alleged to instruct administration of a composition wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL. ¶71 col. 2:4-5
dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL; The proposed labeling is alleged to instruct administration of a composition wherein the dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL or an equivalent thereof. ¶71 col. 2:4-5
NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; The proposed labeling is alleged to instruct administration of a composition wherein the NaCl concentration is from about 6.2 mg/mL to about 9.5 mg/mL. ¶71 col. 2:4-5
and optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol. The proposed labeling is alleged to instruct administration of a composition optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol. ¶71 col. 2:18-20
  • Identified Points of Contention:
    • Scope Question: Infringement of this method claim hinges on inducement. A central question will be whether the specific language in Defendants' final, FDA-approved product label will be found to actively instruct or encourage physicians and patients to perform every step of the claimed method for "treating obesity."
    • Technical Question: As with the '820 Patent, the allegation regarding "dibasic sodium phosphate or equivalent thereof" (Compl. ¶71) suggests a potential dispute over the exact buffer used and whether it infringes literally or under the doctrine of equivalents.

V. Key Claim Terms for Construction

  • The Term: "dibasic sodium phosphate" ('820 Patent, claim 1)
  • Context and Importance: This term is a required excipient in the claimed formulation. The complaint alleges the accused product contains "dibasic sodium phosphate or equivalent thereof" (Compl. ¶55), which suggests Defendants may use a different phosphate buffer. The construction of this term will be critical for determining literal infringement, and its scope will be central to any doctrine of equivalents analysis.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent specification describes the invention's purpose as providing "acceptable stability and acceptable patient injection site experience" ('820 Patent, col. 2:23-25). A party might argue that "dibasic sodium phosphate" should be interpreted to include any phosphate-based buffer that achieves these stated functional goals.
    • Evidence for a Narrower Interpretation: The patent repeatedly and specifically names "dibasic sodium phosphate" in its claims and exemplary tables ('820 Patent, claim 1; '820 Patent, Table 1). A party could argue this consistent, specific language limits the term to the precise chemical entity disodium hydrogen phosphate, excluding other phosphate salts.
  • The Term: "treating obesity" ('623 Patent, claim 1)
  • Context and Importance: As this is a method-of-use claim, the definition of "treating obesity" is fundamental to the infringement analysis, which depends on what the accused product's label instructs users to do (Compl. ¶71). Practitioners may focus on this term because its scope determines whether the act encouraged by the label-administering the drug for weight management-falls within the patent's exclusive rights.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent specification states that tirzepatide is "useful in the treatment of obesity" and defines "treating" as including "providing therapeutic weight loss" ('623 Patent, col. 2:34-35; '623 Patent, col. 3:8-9). This supports an interpretation where administering the drug with the intent to cause weight loss constitutes "treating obesity."
    • Evidence for a Narrower Interpretation: A party might argue that "treating obesity" requires more than just administration, such as achieving a specific, clinically-defined endpoint of weight reduction. While the patent itself may not explicitly provide this narrower definition, such an argument could be advanced to suggest that a label merely offering the possibility of weight loss does not instruct "treating obesity" as claimed.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement. Inducement is primarily based on allegations that Defendants' proposed product labeling will instruct and encourage healthcare providers and patients to administer the generic products in accordance with the patented methods of use and dosing regimens (Compl. ¶63; Compl. ¶79). Contributory infringement is alleged on the basis that the products are especially made for these infringing uses and are not suitable for substantial noninfringing use (Compl. ¶64; Compl. ¶82).
  • Willful Infringement: The complaint alleges that Defendants had pre-suit knowledge of the asserted patents because the patents are listed in the FDA's Orange Book and were identified in the notice letters Defendants sent to Plaintiff (Compl. ¶62; Compl. ¶78). The complaint alleges that, despite this knowledge, Defendants intend to engage in infringing activities, supporting the claim for willful infringement (Compl. ¶¶62-63).

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of infringement by labeling: For the numerous method-of-use patents, the case will hinge on whether the specific instructions, indications, and dosage information on Defendants' final, FDA-approved product label are found to actively encourage medical professionals and patients to perform the exact dosing, titration, and administration steps recited in the asserted claims.
  • A key evidentiary question will be one of formulation equivalence: For the composition patents, a core dispute may arise over the specific excipients used in Defendants' formulation. If the formulation is not identical to that claimed, the analysis will turn on whether any substituted components, such as a different phosphate buffer, perform the same function (e.g., stabilization, pH maintenance) in substantially the same way to achieve the same result, which would be a central question for a doctrine of equivalents analysis.
  • A foundational legal battle will be over patent validity: Defendants have filed Paragraph IV certifications asserting the patents are invalid or unenforceable. Consequently, a primary focus of the litigation will be Defendants' attempt to invalidate the asserted patents based on prior art (obviousness or anticipation) or alleged deficiencies in the patents themselves, such as lack of enablement or written description for the claimed formulations and methods.
Loading Complaint